This invention describes the use of indane acetic acid derivatives which are dual PPAR delta/gamma agonists for the treatment of liver diseases including one or more of the following: NAFLD (Non Alcoholic Fatty Liver Disease), NASH (Non Alcoholic Steatohepatitis), Farber's Disease, ACLF (Acute-on-Chronic Liver Failure), CLF (Chronic Liver Failure), POLT-HCV-SVR (Post-Orthotopic Liver Transplant due to Hepatitis C Virus infection after Sustained Viral Response following anti-HCV therapy), Alagille syndrome, PFIC (Progressive Familial Intrahepatic Cholestasis), PBC (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, ADPCLD (Autosomal Dominant Polycystic Liver Disease), Treatment of liver transplant patients with reestablished fibrosis, CESD (Cholesteryl Ester Storage Disease), SHTG (Severe Hypertriglyceridemia), HoFH (Homozygous Familial Hypercholesterolemia), HE (Hepatic Encephalopathy), or Alcoholic Liver Disease.
